Clik here to view.
AOP...
维也纳 (美国商业资讯)–AOP Health在著名的2022年欧洲血液学协会(EHA)年会上公布了Ropeginterferon alfa-2b（罗培根干扰素α-2b）治疗真性红细胞增多症(PV)患者的最终研究结果。奥地利维也纳医科大学的Heinz Gisslinger教授口头报告了结果1。 摘要链接 罗培根干扰素α-2b是一种长效型单聚乙二醇化脯氨酸干扰素(ATC...
View ArticleClik here to view.
BeiGene Announces Acceptance of Supplemental Biologics License Application in...
CAMBRIDGE, Mass., & BASEL, Switzerland & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and...
View ArticleClik here to view.
InnoCare Announces First Patient Dosed in Clinical Trial of Novel SHP2...
BEIJING InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in...
View ArticleClik here to view.
Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for...
TOKYO & MUNICH Daiichi Sankyo (TSE: 4568) today announced that the European Medicines Agency (EMA) has validated the Type II Variation application for trastuzumab deruxtecan as monotherapy for...
View ArticleClik here to view.
AOPヘルスが真性多血症患者をBESREMi®（ロペグインターフェロンアルファ-2b）で最長7.5年間にわたり治療したCONTINUATION-PV試験の...
ウィーン （ビジネスワイヤ） — AOPヘルスは、権威ある欧州血液学会（EHA）の2022年度総会でオーストリアのウィーン医科大学のハインツ・ギスリンガー教授が口頭発表にて、真性多血症（PV）患者をロペグインターフェロンアルファ-2bで治療したCONTINUATION-PV試験の最終結果を報告したと発表しました1。 アブストラクトへのリンク...
View ArticleClik here to view.
PharmaEssentia Honored at the National Organization of Rare Disorders (NORD®)...
BURLINGTON, Mass. PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven...
View ArticleClik here to view.
Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA® ▼(burosumab)...
TOKYO Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended that...
View ArticleClik here to view.
Trastuzumab Deruxtecan Recommended for Approval in the EU by CHMP for...
TOKYO & MUNICH Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) trastuzumab deruxtecan has been recommended for approval in the European Union (EU) as a monotherapy for the...
View ArticleClik here to view.
US FDA Approves Prestige Biopharma’s IND for Phase 1/2a Trial of...
SINGAPORE Prestige Biopharma Limited, a Singapore-based biopharmaceutical company with operations in USA and South Korea, announced that the U.S. Food and Drug Administration (FDA) has approved the...
View ArticleClik here to view.
BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival...
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and...
View ArticleClik here to view.
Twist Bioscience and Ildong Pharmaceutical Enter into a Collaboration to...
SOUTH SAN FRANCISCO, Calif. & SEOUL, South Korea Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its...
View ArticleClik here to view.
Aurigene Discovery Technologies Limited Announces Drug Discovery, Development...
BENGALURU, India The collaboration combines Aurigene’s small molecule drug discovery platform and EQRx’s pioneering business model to accelerate the development of drug candidates in the areas of...
View ArticleClik here to view.
CANbridge Appoints Industry Leader Edward Hu to the Board
BEIJING & CAMBRIDGE, Mass. CANbridge Pharmaceuticals Inc. (HKEX:1228), a China and US-based global biopharmaceutical company committed to the research, development and commercialization of...
View ArticleClik here to view.
Turnstone Biologics and Moffitt Cancer Center Announce Strategic Alliance to...
NEW YORK & TAMPA, Fla. Turnstone Biologics Corp., a clinical-stage biotechnology company developing next-generation immunotherapies to treat and cure solid tumors, and Moffitt Cancer Center...
View ArticleClik here to view.
BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly...
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and...
View ArticleClik here to view.
Aurigene Discovery Technologies Limited宣布与EQRx建立药物发现、开发和商业化合作伙伴关系
印度班加罗尔 (美国商业资讯)–双方的合作将Aurigene的小分子药物发现平台和EQRx的开创性商业模式进行整合，从而加快肿瘤和免疫炎症疾病领域候选药物的开发，改善全球创新药物的获取途径。...
View ArticleClik here to view.
InnoCare Announces Approval of Clinical Trial of Novel Targeted Protein...
BEIJING InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the company has received Investigational...
View ArticleClik here to view.
PHC株式会社：PHCbi、独自の電気化学式センサー技術を活用した研究用「ライブセル代謝分析装置」のプロトタイプを開発～細胞治療の産業化に向けた課題解決へ...
東京 （ビジネスワイヤ） — ライフサイエンス分野において研究・医療支援機器およびサービスをグローバルに提供するPHC株式会社 バイオメディカ事業部（以下、「PHCbi」）は、7月13日（水）から7月15日（金）まで東京ビッグサイトで開催される「第4回ファーマラボEXPO東京」（主催：RX...
View ArticleClik here to view.
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for...
GUANGZHOU, China Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase 1 clinical study evaluating BAT8006, an antibody...
View ArticleClik here to view.
BeiGene Appoints Chan Lee as General Counsel
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology biotechnology company focused on developing and commercializing innovative...
View Article